Oncology

Non-Small Cell Lung Cancer

Expert Roundtables Podcast: The Application of Precision Medicine Across Non–Small Cell Lung Cancer Stages

expert roundtables by Charu Aggarwal, MD, MPH, FASCO; Narjust Florez, MD, FASCO; Helena A. Yu, MD

Overview

Precision medicine is increasingly guiding treatment across the non–small cell lung cancer (NSCLC) continuum, from perioperative chemoimmunotherapy for driver-negative disease to genotype-directed therapy for selected driver-positive tumors. In this NSCLC podcast, our featured experts discuss molecular testing, evidence supporting targeted and immunotherapy approaches, and the challenges of extending clinical trial findings to rare molecular subgroups.

References

Barlesi F, Cho BC, Goldberg SB, et al. PACIFIC-9: phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137-2147. doi:10.1080/14796694.2024.2354160

Forde PM, Spicer JD, Provencio M, et al; CheckMate 816 Investigators. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393(8):741-752. doi:10.1056/NEJMoa2502931

He J, Tsuboi M, Weder W, et al; NeoADAURA Investigators. Neoadjuvant osimertinib for resectable EGFR-mutated non–small cell lung cancer. J Clin Oncol. 2025;43(26):2875-2887. doi:10.1200/JCO-25-00883

Leonetti A, Boni L, Gnetti L, et al. Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of the ALNEO phase II trial (GOIRC-01-2020-ML42316). J Clin Oncol. 2025;43(suppl 16):8015. doi:10.1200/JCO.2025.43.16_suppl.8015

Lu S, Kato T, Dong X, et al; LAURA Trial Investigators. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585-597. doi:10.1056/NEJMoa2402614

Wakelee H, Spicer JD, Gao S, et al. Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study. Ann Oncol. Published online August 21, 2026. doi:10.1016/j.annonc.2026.08.005

Wu YL, Dziadziuszko R, Ahn JS, et al; ALINA Investigators. Alectinib in resected ALK-positive non–small-cell lung cancer. N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532

Wu YL, Hochmair M, Yang Y, et al; LIBRETTO-432 Trial Investigators. Selpercatinib in early-stage RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2026;395(7):660-670. doi:10.1056/NEJMoa2602628

Profile

Charu Aggarwal, MD, MPH, FASCO

Leslye M. Heisler Professor for Lung Cancer Excellence
Section Chief, Thoracic and Head and Neck Cancers
Division of Hematology and Oncology
Physician Leader, Airways Malignancies Research Program
Director, Precision Oncology Program, Penn Center for Cancer Care Innovation
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Profile

Narjust Florez, MD, FASCO

Associate Medical Director, Cancer Care Access Program
Codirector, Young Lung Cancer Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Profile

Helena A. Yu, MD

Professor of Medicine
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Oncology

Non-Small Cell Lung Cancer

Expert Roundtables Podcast: The Application of Precision Medicine Across Non–Small Cell Lung Cancer Stages

Charu Aggarwal, MD, MPH, FASCO

Narjust Florez, MD, FASCO

Helena A. Yu, MD

Explore More in Non-Small Cell Lung Cancer

Expert Roundtables Podcast: Targeted Therapies for Mutation-Driven Non–Small Cell Lung Cancer

Clinical Topic Updates Podcast: Neoadjuvant, Perioperative, and Adjuvant Therapies for Resectable Non–Small Cell Lung Cancer

Patient Care Perspectives Podcast: The Multimodal Treatment of Non–Small Cell Lung Cancer

The Utility of Blood-Based Biomarkers for Advanced Non–Small Cell Lung Cancer